{"id":54078,"date":"2023-02-21T01:03:24","date_gmt":"2023-02-21T00:03:24","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/biocytogen-launches-nano-100-project-to-develop-fully-human-nanobody-therapeutics-for-over-100-targets\/"},"modified":"2023-02-21T01:03:24","modified_gmt":"2023-02-21T00:03:24","slug":"biocytogen-launches-nano-100-project-to-develop-fully-human-nanobody-therapeutics-for-over-100-targets","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/biocytogen-launches-nano-100-project-to-develop-fully-human-nanobody-therapeutics-for-over-100-targets\/","title":{"rendered":"Biocytogen Launches \u201cNano 100 Project\u201d to Develop Fully Human Nanobody Therapeutics for Over 100 Targets"},"content":{"rendered":"
\n

BEIJING–(BUSINESS WIRE)–#Antibody<\/a>–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced the launch of the \u201cNano 100 Project\u201d, which aims to develop fully human nanobody drugs for over 100 targets. The Project combines Biocytogen\u2019s proprietary fully human nanobody mouse, RenNanoTM<\/sup>, with its high-throughput in vitro<\/i> and in vivo<\/i> antibody screening platforms to develop fully human nanobody drugs on a large-scale.\n<\/p>\n

<\/a><\/p>\n

\nCompared to traditional antibodies, nanobodies have smaller molecular weights and improved tissue penetration ability, which make them effective at infiltrating tumors and crossing blood-brain barriers. Additionally, nanobodies generally have longer CDR3 regions which enables them to recognize hidden epitopes better. Due to their simpler structure, nanobodies are more stable and easier to produce and engineer, making them ideal building blocks for complex modalities such as cell therapy, bispecific antibody and engager, multi-specific antibody, antibody drug-conjugate (ADC), and radionuclide antibody-conjugate (RAC).\n<\/p>\n

\nAfter several years of endeavor, Biocytogen successfully engineered the RenNano mouse from its fully human antibody mouse, RenMabTM<\/sup>. RenNano mouse possesses full human heavy chain variable regions and can produce heavy-chain-only antibodies (HCAbs). The variable regions of HCAbs, i.e., nanobodies, do not require in vitro<\/i> humanization to develop drugs. Our research has shown that RenNano mouse can generate robust immune responses after immunizations by different antigens. HCAbs generated from the RenNano mouse have highly diverse CDR3 sequences and can recognize many epitopes with nM-level high affinities. In vitro<\/i> and in vivo<\/i> experiments have shown that RenNano-derived antibodies have favorable biological functions.\n<\/p>\n

\nBased on RenNano\u2019s excellent ability to discover fully human nanobodies, Biocytogen has launched the \u201cNano 100 Project\u201d. The Project aims to develop fully human therapeutic nanobodies against over 100 targets, including tumor associated antigens (TAAs), GPCRs, immune-checkpoints, cytokines, and factors related to neurological diseases. Biocytogen is actively seeking collaborations with global pharmaceutical and biotech companies to combine its large-scale nanobody development abilities with collaborators\u2019 expertise in nanobody-related therapeutics, such as cell therapies, bispecific and multi-specific antibodies, ADCs and RACs, to develop novel drugs with first-in-class and\/or best-in-class potentials.\n<\/p>\n

\n\u201cWe believe that with the ability to rapidly develop fully human nanobodies against selected targets, the \u2018Nano 100 Project\u2019 will provide our global partners with more diverse and better nanobody building blocks to accelerate the development of novel drugs,\u201d said Dr. Yuelei Shen, President and CEO of Biocytogen. \u201cMeanwhile, it is also an important supplement to Biocytogen\u2019s Project Integrum.\u201d\n<\/p>\n

\nAbout RenNano<\/a><\/b>TM<\/sup>\n<\/p>\n

\nBiocytogen’s proprietary fully human nanobody generating mouse, RenNano, is one of the most comprehensive fully human antibody platforms in the world. Nanobody sequences generated from RenNano mice have the highest possible diversity and do not require antibody humanization, which saves time and cost and reduces the risk of failure during later stages of drug development. Additionally, compared to natural HCAb-producing species like camelids, mice are easier to breed and immunize, making them suitable for developing HCAbs on a large scale.\n<\/p>\n

\nAbout Biocytogen<\/b>\n<\/p>\n

\nBiocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM<\/sup>\/RenLiteTM<\/sup>\/RenNanoTM<\/sup> mice platforms for fully human monoclonal antibody, bispecific\/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo<\/i> drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and\/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum<\/a>. This project has resulted in 28 drug co-development agreements and 16 RenMiceTM<\/sup> licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen’s pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http:\/\/en.biocytogen.com.cn<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nBiocytogen\u2019s Contacts<\/b>
Antibody platforms and antibody assets: BD-Licensing@biocytogen.com<\/a>
Media: pr@bbctg.com.cn<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BEIJING–(BUSINESS WIRE)–#Antibody–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced the launch of the \u201cNano 100 Project\u201d, which aims to develop fully human nanobody drugs for over 100 targets. The Project combines Biocytogen\u2019s proprietary fully human nanobody mouse, RenNanoTM, with its high-throughput in vitro and in vivo antibody screening platforms to develop fully human … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54078","6":"format-standard","7":"category-industry"},"yoast_head":"\nBiocytogen Launches \u201cNano 100 Project\u201d to Develop Fully Human Nanobody Therapeutics for Over 100 Targets - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/biocytogen-launches-nano-100-project-to-develop-fully-human-nanobody-therapeutics-for-over-100-targets\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biocytogen Launches \u201cNano 100 Project\u201d to Develop Fully Human Nanobody Therapeutics for Over 100 Targets - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BEIJING–(BUSINESS WIRE)–#Antibody–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced the launch of the \u201cNano 100 Project\u201d, which aims to develop fully human nanobody drugs for over 100 targets. The Project combines Biocytogen\u2019s proprietary fully human nanobody mouse, RenNanoTM, with its high-throughput in vitro and in vivo antibody screening platforms to develop fully human ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/biocytogen-launches-nano-100-project-to-develop-fully-human-nanobody-therapeutics-for-over-100-targets\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-21T00:03:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230220005141\/en\/1717564\/21\/Biocytogen%27s_LOGO.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-launches-nano-100-project-to-develop-fully-human-nanobody-therapeutics-for-over-100-targets\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-launches-nano-100-project-to-develop-fully-human-nanobody-therapeutics-for-over-100-targets\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Biocytogen Launches \u201cNano 100 Project\u201d to Develop Fully Human Nanobody Therapeutics for Over 100 Targets\",\"datePublished\":\"2023-02-21T00:03:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-launches-nano-100-project-to-develop-fully-human-nanobody-therapeutics-for-over-100-targets\\\/\"},\"wordCount\":663,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-launches-nano-100-project-to-develop-fully-human-nanobody-therapeutics-for-over-100-targets\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230220005141\\\/en\\\/1717564\\\/21\\\/Biocytogen%27s_LOGO.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-launches-nano-100-project-to-develop-fully-human-nanobody-therapeutics-for-over-100-targets\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-launches-nano-100-project-to-develop-fully-human-nanobody-therapeutics-for-over-100-targets\\\/\",\"name\":\"Biocytogen Launches \u201cNano 100 Project\u201d to Develop Fully Human Nanobody Therapeutics for Over 100 Targets - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-launches-nano-100-project-to-develop-fully-human-nanobody-therapeutics-for-over-100-targets\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-launches-nano-100-project-to-develop-fully-human-nanobody-therapeutics-for-over-100-targets\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230220005141\\\/en\\\/1717564\\\/21\\\/Biocytogen%27s_LOGO.jpg\",\"datePublished\":\"2023-02-21T00:03:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-launches-nano-100-project-to-develop-fully-human-nanobody-therapeutics-for-over-100-targets\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-launches-nano-100-project-to-develop-fully-human-nanobody-therapeutics-for-over-100-targets\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-launches-nano-100-project-to-develop-fully-human-nanobody-therapeutics-for-over-100-targets\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230220005141\\\/en\\\/1717564\\\/21\\\/Biocytogen%27s_LOGO.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230220005141\\\/en\\\/1717564\\\/21\\\/Biocytogen%27s_LOGO.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-launches-nano-100-project-to-develop-fully-human-nanobody-therapeutics-for-over-100-targets\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biocytogen Launches \u201cNano 100 Project\u201d to Develop Fully Human Nanobody Therapeutics for Over 100 Targets\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biocytogen Launches \u201cNano 100 Project\u201d to Develop Fully Human Nanobody Therapeutics for Over 100 Targets - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/biocytogen-launches-nano-100-project-to-develop-fully-human-nanobody-therapeutics-for-over-100-targets\/","og_locale":"en_US","og_type":"article","og_title":"Biocytogen Launches \u201cNano 100 Project\u201d to Develop Fully Human Nanobody Therapeutics for Over 100 Targets - Pharma Trend","og_description":"BEIJING–(BUSINESS WIRE)–#Antibody–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced the launch of the \u201cNano 100 Project\u201d, which aims to develop fully human nanobody drugs for over 100 targets. The Project combines Biocytogen\u2019s proprietary fully human nanobody mouse, RenNanoTM, with its high-throughput in vitro and in vivo antibody screening platforms to develop fully human ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/biocytogen-launches-nano-100-project-to-develop-fully-human-nanobody-therapeutics-for-over-100-targets\/","og_site_name":"Pharma Trend","article_published_time":"2023-02-21T00:03:24+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230220005141\/en\/1717564\/21\/Biocytogen%27s_LOGO.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/biocytogen-launches-nano-100-project-to-develop-fully-human-nanobody-therapeutics-for-over-100-targets\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/biocytogen-launches-nano-100-project-to-develop-fully-human-nanobody-therapeutics-for-over-100-targets\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Biocytogen Launches \u201cNano 100 Project\u201d to Develop Fully Human Nanobody Therapeutics for Over 100 Targets","datePublished":"2023-02-21T00:03:24+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/biocytogen-launches-nano-100-project-to-develop-fully-human-nanobody-therapeutics-for-over-100-targets\/"},"wordCount":663,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/biocytogen-launches-nano-100-project-to-develop-fully-human-nanobody-therapeutics-for-over-100-targets\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230220005141\/en\/1717564\/21\/Biocytogen%27s_LOGO.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/biocytogen-launches-nano-100-project-to-develop-fully-human-nanobody-therapeutics-for-over-100-targets\/","url":"https:\/\/pharma-trend.com\/en\/biocytogen-launches-nano-100-project-to-develop-fully-human-nanobody-therapeutics-for-over-100-targets\/","name":"Biocytogen Launches \u201cNano 100 Project\u201d to Develop Fully Human Nanobody Therapeutics for Over 100 Targets - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/biocytogen-launches-nano-100-project-to-develop-fully-human-nanobody-therapeutics-for-over-100-targets\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/biocytogen-launches-nano-100-project-to-develop-fully-human-nanobody-therapeutics-for-over-100-targets\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230220005141\/en\/1717564\/21\/Biocytogen%27s_LOGO.jpg","datePublished":"2023-02-21T00:03:24+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/biocytogen-launches-nano-100-project-to-develop-fully-human-nanobody-therapeutics-for-over-100-targets\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/biocytogen-launches-nano-100-project-to-develop-fully-human-nanobody-therapeutics-for-over-100-targets\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/biocytogen-launches-nano-100-project-to-develop-fully-human-nanobody-therapeutics-for-over-100-targets\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230220005141\/en\/1717564\/21\/Biocytogen%27s_LOGO.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230220005141\/en\/1717564\/21\/Biocytogen%27s_LOGO.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/biocytogen-launches-nano-100-project-to-develop-fully-human-nanobody-therapeutics-for-over-100-targets\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Biocytogen Launches \u201cNano 100 Project\u201d to Develop Fully Human Nanobody Therapeutics for Over 100 Targets"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54078","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54078"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54078\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54078"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54078"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54078"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}